BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The company Merck KGaA submitted on 1 July 2003 an application for Marketing Authorisation to 
the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for  Erbitux,  in  accordance 
with the centralised procedure falling within the scope of Part A of the Annex to Council Regulation 
No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr Per Nilsson 
Co-Rapporteur:  Dr Manfred Haase 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 21 July 2003. 
The Rapporteur's first assessment report was circulated to all CPMP Members on 29 September 
2003. The Co-Rapporteur's first assessment report was circulated to all CPMP Members on 29 
September 2003. 
During  the  3-5  November  2003  meeting  the  BWP  adopted  the  BWP  report  with  a 
recommendation  to  the  CPMP  incorporating  the  draft  List  of  Questions  to  be  adopted  at  the 
November 2003 CPMP meeting. 
During  the  meeting  on  18-20  November  2003,  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  21 November 2003. 
The  company  submitted  the  responses  to  the  consolidated  List  of  Questions  on  16  December 
2003. 
The Rapporteurs circulated the joint assessment report on the applicant’s responses to the List 
of Questions to all CPMP members on 30 January 2004 
During the CPMP meeting on 24-26 February 2004, the CPMP agreed on a List of Outstanding 
Issues to be addressed in writing by the applicant. 
The  applicant  submitted  the  responses  to  the  CPMP’s  List  of  Outstanding  Issues  on  5  March 
2004. 
The Rapporteurs circulated the updated joint assessment report on the applicant’s responses to 
the List of Outstanding Issues on 12 March 2004. 
During the meeting on 23-24 March 2004 the CPMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Erbitux on 24 March 2004. 
The  CPMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 29 June 2004. 
1/1 
EMEA 2004 
 
